• / Free eNewsletters & Magazine
  • / My Account

AES

The AES Corporation AES 3 Star

Last Price$14.55Day Change (%)-1.02%
Open Price$14.65Day Change ($)-0.15
Day Range14.50–14.6852-Week Range13.16–15.65

As of Tue 09/23/2014 04:10 AM EST | USD

  1. All
  2. Morningstar Articles
  3. 3rd Party
  4. Investing
  1. AES President and CEO Andrés Gluski to Present at 2014 Barclays CEO Energy-Power Conference

    AES President and CEO Andrés Gluski to Present at 2014 Barclays CEO Energy-Power Conference

  2. Type 2 Diabetes: Investigational empagliflozin/linagliptin combination tablet shows sustained reduction in blood glucose in Phase III study

    Type 2 Diabetes: Investigational empagliflozin/linagliptin combination tablet shows sustained reduction in blood glucose in Phase III study

  3. to-BBB Announces Positive Data from Phase 1 Clinical Study

    to-BBB Announces Positive Data from Phase 1 Clinical Study

  4. Research and Markets: Global Wind Power (Installed Capacity - Cumulative and New Capacity) Market in Megawatts 2014-2020

    Research and Markets: Global Wind Power (Installed Capacity - Cumulative and New Capacity) Market in Megawatts 2014-2020

  5. A Billion Devices on LTE Networks by 2017 Face BYOD Security Threat, Says Vitesse

    A Billion Devices on LTE Networks by 2017 Face BYOD Security Threat, Says Vitesse

  6. CytRx Initiates Phase 1b Clinical Trial with Combination of Aldoxorubicin and Ifosfamide/Mesna as First-Line Treatment in Patients with Advanced Sarcomas

    CytRx Initiates Phase 1b Clinical Trial with Combination of Aldoxorubicin and Ifosfamide/Mesna as First-Line Treatment in Patients with Advanced Sarcomas

  7. Brigade Urges Syncora Preference Shareholders to Vote "For" Carr and Wells as Directors

    Brigade Urges Syncora Preference Shareholders to Vote "For" Carr and Wells as Directors

  8. Brigade Provides Update on Special General Meeting Of Syncora Preference Shareholders

    Brigade Provides Update on Special General Meeting Of Syncora Preference Shareholders

  9. Amgen Announces Positive Top-Line Results From Phase 3 YUKAWA-2 Trial Of Evolocumab In Combination With Statins In Japanese Patients With High Cardiovascular Risk And High Cholesterol

    Amgen Announces Positive Top-Line Results From Phase 3 YUKAWA-2 Trial Of Evolocumab In Combination With Statins In Japanese Patients With High Cardiovascular Risk And High Cholesterol

  10. What to Do With Exelon?

    Pepco deal, power prices, capacity markets, carbon caps: It’s been a wild ride for Exelon in 2014.

12
Upcoming Events
Conferences
Webinars

©2014 Morningstar Advisor. All right reserved.